Latham & Watkins LLP represented the underwriters in the offering. Aclaris Therapeutics, Inc. completed its underwritten public offering of 5,483,714 shares of its common stock at…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
